Functional development of a V3-specific broadly neutralizing antibody isolated from a case of HIV superinfection

Mackenzie M. Shipley, Vidya Mangala Prasad, Duncan Ralph, Elias Harkins, Amrit Dhar, F. A. Matsen, Kelly K. Lee, Overbaugh, Julie M.Zenodo 2021 · DOI

Abstract: Stimulating broadly neutralizing antibodies (bnAbs) directly from germline remains a barrier for HIV vaccines. HIV superinfection elicits bnAbs more frequently than single infection, providing clues of how to elicit such responses. We used longitudinal antibody sequencing and structural studies to characterize bnAb development from a superinfection case. Mature bnAb QA013.2 bound both initial transmitted and superinfecting virus, but its inferred naïve bound only the superinfecting strain and was not neutralizing. QA013.2 requires residues spanning FWRH1-CDRH1 to attain breadth, which is uncommon for V3-specific bnAbs. A 4.15 Å cryo-EM structure of QA013.2 bound to heterologous native-like trimer showed recognition of V3 signatures (N301, N332, and GDIR). Antigenic profiling revealed that viral escape was achieved not only by changes in the structurally-defined epitope, but also by mutations in V1. These results highlight shared and distinct properties of QA013.2 relative to other V3-specific bnAbs in the setting of sequential, diverse antigenic variants.

Introduction

The development of a vaccine capable of eliciting broadly neutralizing antibodies (bnAbs) is a primary goal of HIV research. Most bnAbs require years of maturation and extensive somatic hypermutation (SHM), making them difficult to induce through standard immunization protocols. However, individuals who experience HIV superinfection (SI)—infection with a second, genetically distinct strain—often develop broader antibody responses more frequently than those with a single infection. This study investigates the functional evolution of QA013.2, a V3-specific bnAb isolated from an SI case, to understand how sequential exposure to diverse antigenic variants shapes the immune response.

Methods

Researchers employed a multi-disciplinary approach to reconstruct the antibody's lineage and characterize its function:

  • Longitudinal NGS & Lineage Reconstruction: Deep sequencing of antibody repertoires from blood samples collected over six years was analyzed using Bayesian phylogenetics and hidden Markov models (linearham and partis) to infer the ancestral naïve B cell receptor.
  • Cryo-Electron Microscopy (Cryo-EM): A 4.15 Å structure of the QA013.2 Fab bound to a native-like HIV Envelope (Env) trimer was solved to map the physical interface.
  • Mutational Antigenic Profiling: Deep mutational scanning of the HIV Env identified viral escape pathways.
  • Binding & Neutralization Assays: Chimeric antibodies were synthesized to pinpoint mutations conferring neutralization breadth against a panel of heterologous "Tier 2" pseudoviruses.

Results

Timeline of superinfection and the reconstructed evolutionary lineage of the QA013.2 bnAb.

The Role of Superinfection in Lineage Seeding

Lineage reconstruction revealed that the inferred naïve version of QA013.2 could bind the superinfecting strain (clade A) but not the initial infecting strain (clade D). This suggests that the second infection was the primary driver that "seeded" this specific bnAb lineage. The mature antibody eventually developed the ability to neutralize a wide range of global HIV subtypes, with IC50 values as low as 0.06 µg/mL.

Unconventional Structural Requirements for Breadth

While most V3-targeting antibodies rely heavily on the CDRH3 loop, QA013.2 exhibits a unique dependence on residues in the framework region 1 (FWRH1) and CDRH1 of the heavy chain. Reverting just six residues in these regions to their naïve state completely abolished broad neutralization. The mature antibody achieved significant breadth with approximately 18-20% SHM (82% identity to germline for VH), which is lower than many other bnAb classes, suggesting it may be a more attainable target for vaccine design.

Structural Interface and Viral Escape

The 4.15 Å cryo-EM structure confirmed that QA013.2 recognizes the conserved "GDIR" peptide motif and glycans N332 and N301 at the V3 supersite, albeit with a unique "tilted" orientation. Interestingly, mutational profiling showed that the virus could escape neutralization through mutations in the V1 loop, which is not part of the primary binding site. This suggests the V1 loop may indirectly interfere with the antibody's specific angle of approach.

Discussion

QA013.2 provides a blueprint for how sequential exposure to diverse antigens can guide the immune system toward breadth. The discovery that FWRH1 and CDRH1 mutations are critical for its function expands our understanding of V3-specific bnAb maturation.

However, limitations remain. Dense longitudinal sampling was missing between years 2 and 6, a period where over 70% of the mature mutations likely accumulated. Additionally, while the 4.15 Å structure provides a clear map of the interaction, higher resolution is needed to define specific atomic-level contacts. Future work will focus on designing vaccine immunogens that can mimic the "one-two punch" of sequential infection observed in this superinfection case.

Summary updated

Abstract

Stimulating broadly neutralizing antibodies (bnAbs) directly from germline remains a barrier for HIV vaccines. HIV superinfection elicits bnAbs more frequently than single infection, providing clues of how to elicit such responses. We used longitudinal antibody sequencing and structural studies to characterize bnAb development from a superinfection case. Mature bnAb QA013.2 bound both initial transmitted and superinfecting virus, but its inferred naïve bound only the superinfecting strain and was not neutralizing. QA013.2 requires residues spanning FWRH1-CDRH1 to attain breadth, which is uncommon for V3-specific bnAbs. A 4.15 Å cryo-EM structure of QA013.2 bound to heterologous native-like trimer showed recognition of V3 signatures (N301, N332, and GDIR). Antigenic profiling revealed that viral escape was achieved not only by changes in the structurally-defined epitope, but also by mutations in V1. These results highlight shared and distinct properties of QA013.2 relative to other V3-specific bnAbs in the setting of sequential, diverse antigenic variants.
BibTeX
@inproceedings{shipley2021functional,
  author = {Mackenzie M. Shipley and Vidya Mangala Prasad and Duncan Ralph and Elias Harkins and Amrit Dhar and F. A. Matsen and Kelly K. Lee and Overbaugh, Julie M.},
  title = {{Functional development of a V3-specific broadly neutralizing antibody isolated from a case of HIV superinfection}},
  booktitle = {Zenodo},
  year = {2021},
  doi = {10.5281/zenodo.4574672},
}

Loading related content...

Figure